Lucid Diagnostics Inc (NASDAQ: LUCD) on Friday, soared 3.96% from the previous trading day, before settling in for the closing price of $0.98. Within the past 52 weeks, LUCD’s price has moved between $0.73 and $1.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -54.43% annually for the last half of the decade. The company achieved an average annual earnings per share of 34.43%. With a float of $40.45 million, this company’s outstanding shares have now reached $101.83 million.
In an organization with 72 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -34.49%, operating margin of -979.3%, and the pretax margin is -385.0%.
Lucid Diagnostics Inc (LUCD) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Lucid Diagnostics Inc is 62.71%, while institutional ownership is 18.64%. The most recent insider transaction that took place on May 20 ’25, was worth 242,292. In this transaction Director of this company bought 187,098 shares at a rate of $1.29, taking the stock ownership to the 187,098 shares. Before that another transaction happened on May 21 ’25, when Company’s Director bought 129,684 for $1.32, making the entire transaction worth $171,520. This insider now owns 316,782 shares in total.
Lucid Diagnostics Inc (LUCD) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.2 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.18) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.08% during the next five years compared to -54.43% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
Lucid Diagnostics Inc (LUCD) is currently performing well based on its current performance indicators. A quick ratio of 1.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was inferior than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.21%.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 8.29%, which indicates a significant decrease from 43.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0569 in the past 14 days, which was lower than the 0.0863 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1227, while its 200-day Moving Average is $1.1398. However, in the short run, Lucid Diagnostics Inc’s stock first resistance to watch stands at $1.0330. Second resistance stands at $1.0459. The third major resistance level sits at $1.0719. If the price goes on to break the first support level at $0.9941, it is likely to go to the next support level at $0.9681. Assuming the price breaks the second support level, the third support level stands at $0.9552.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
Market capitalization of the company is 110.65 million based on 108,477K outstanding shares. Right now, sales total 4,350 K and income totals -45,530 K. The company made 830 K in profit during its latest quarter, and -26,910 K in sales during its previous quarter.
